International Study of Biofield Therapy

June 19, 2019 updated by: Kiyoshi Suzuki, MOA Health Science Foundation

International Cross-sectional Study on the Effectiveness of Biofield Therapy for the Relief of Various Symptoms

Participants from 14 different countries received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners. Before and after the therapy, they reported the severity of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the effectiveness/safety of biofield therapy between countries and analyzed the factors associated with the outcomes.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Participants aged 16 or older from 14 different countries (Japan, USA, Argentina, Brazil, Chile, Mexico, Peru, Taiwan, Thai, South Korea, Belgium, France, Portugal, and Spain) received a single session of biofield therapy (Okada Purifying Therapy) lasting 30 minutes or longer from the volunteer practitioners in their country of residence. Before and after the intervention, they reported each severity level of physical pain, anxiety/depression, dizziness/palpitation, and overall symptoms. The team compared the improvement/exacerbation rate of a single session of biofield therapy between the countries, and examined the adjusted odds ratio of the variables associated with the changes in each category of symptoms in a real-world setting.

Study Type

Observational

Enrollment (Actual)

12000

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years and older (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Participants were recruited in various settings, including the workshop, the investigator's house, or the participant's home in 14 different countries.

Description

Inclusion Criteria:

  1. Individuals who agreed to receive a single session of biofield therapy for 30 minutes or longer from the volunteer investigators.
  2. Individuals who were able to self-evaluate the change of their symptoms.
  3. Individuals who were competent to answer the questionnaires.
  4. Individuals who were aged 16 or older.

Exclusion Criteria:

  • no specific exclusion criteria

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Observational Models: Case-Only
  • Time Perspectives: Cross-Sectional

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
improvement/exacerbation rate of symptoms after a single session of biofield therapy
Time Frame: Up to one year after all the data were collected.
The Mann-Whitney test was conducted to compare the improvement/exacerbation rates between countries.
Up to one year after all the data were collected.
adjusted odds ratio of the factors associated with the changes in symptoms
Time Frame: Up to one year after all the data were collected.
Logistic regression analyses
Up to one year after all the data were collected.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

MOA Health Science Foundation

Investigators

  • Study Chair: Kiyoshi Suzuki, MD, PhD, MOA Health Science Foundation

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2008

Primary Completion (Actual)

September 30, 2010

Study Completion (Actual)

September 30, 2010

Study Registration Dates

First Submitted

June 17, 2019

First Submitted That Met QC Criteria

June 19, 2019

First Posted (Actual)

June 21, 2019

Study Record Updates

Last Update Posted (Actual)

June 21, 2019

Last Update Submitted That Met QC Criteria

June 19, 2019

Last Verified

June 1, 2019

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • MOA-004

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Pain

Clinical Trials on Okada Purifying Therapy

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Czech Republic

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe